Press Releases
May. 25, 2018 Bioasis to Present at the 25th Annual BIO International Convention
Bioasis will present at the 25th Annual BIO International Convention, to be held June 4-7, 2018 at the Boston Convention & Exhibition Center.
May. 24, 2018 Bioasis Announces Closing of Second Tranche of Previously Disclosed Private Placement
This News Release is Not for Distribution to U.S. Newswire Services or Dissemination in the United States
May. 21, 2018 Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of xB3-001, the Company’s Lead Investigational Candidate to Treat Brain Cancer
Bioasis will draw on WuXi Biologics’ expertise in developing complex biologic molecules for production of xB 3 -001 to support analytical development, formulation and IND-enabling in vivo studies
May. 17, 2018 Bioasis Announces Closing of First Tranche of Previously Disclosed Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
May. 14, 2018 Bioasis Announces Private Placement and Intention to Pursue NASDAQ Listing
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Mar. 26, 2018 Bioasis Announces Key Strategic Appointment to its Senior Leadership Team with Addition of Caroline Hill, Ph.D., Leading Research & Development Operations
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company with a proprietary blood-brain barrier platform delivery technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases, today announced a key strategic appointment to its senior leadership team with the addition of Caroline Hill, Ph.D.,… Read more »
Mar. 21, 2018 Bioasis Appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as Chair of the Board of Directors
Dr. Rathjen is the Chief Executive Officer and Managing Director of Bionomics in Adelaide, Australia; Dr. Rathjen joined the Bioasis Board in September 2017
Feb. 6, 2018 Bioasis to Present at the 20th Annual BIO CEO & Investor Conference
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that it will present at the 20th Annual BIO CEO & Investor Conference, to be held February 12-13, 2018 at the New York Marriott Marquis. Mark Day, Ph.D., president and chief executive officer, Bioasis, will present at the BIO CEO &… Read more »
Jan. 30, 2018 Bioasis Announces Filing of Quarterly Financial Statements and MD&A
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier (BBB) and into the central nervous system for the treatment of neurological diseases and disorders, today announced that it has filed its unaudited quarterly financial statements and management’s discussion and… Read more »
Jan. 8, 2018 updated: Bioasis to Present at the 2018 Biotech Showcase Annual Conference
Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that it will present at the Biotech Showcase™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.